BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS
MINNEAPOLIS, April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.
- Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications.
- RNAscope is the most referenced technology in the industry, with its rapidly growing portfolio of peer-reviewed publications recently surpassing 10,000.
- In its lawsuit filed in the Unified Patent Court (a pan-European forum for resolving patent disputes), in the Netherlands Local Division of the Court of First Instance in The Hague, Bio-Techne alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439.
- The lawsuit seeks damages and injunctive relief requiring Molecular Instruments to stop infringing ACD's patents in key European markets.